AstraZeneca plc using EPIC/TICKER code (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Liberum Capital. AstraZeneca plc are listed ...

AstraZeneca (LON:AZN) Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma, the most ...

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (known as Merck & Co., Inc. inside the US and Canada) today announced that a supplemental New Drug Application for Lynparza has been accepted and ...

AstraZeneca plc using EPIC/TICKER code (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OUTPERFORM’ this morning by analysts at Credit Suisse. AstraZeneca plc ...

Shares of Applied Graphene Materials EPIC code: LON:AGM has risen 9.68% or 1.5 points throughout today’s trading session so far. Market buyers have remained optimistic during the session. The high ...

Following the recommendation from an independent Data Monitoring Committee, AstraZeneca (LON:AZN) has decided to close the Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) due to its low likelihood of demonstrating ...

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) has today announced that a supplemental New Drug Application for Lynparza (olaparib) in ...

AstraZeneca plc with EPIC/TICKER (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘EQUAL WEIGHT’ today by analysts at Morgan Stanley. AstraZeneca plc are listed ...

AstraZeneca (LON:AZN) has announced today that Lokelma has been approved in China for the treatment of adult patients with hyperkalaemia. The approval by the National Medical Products Administration (NMPA) was based on ...

AstraZeneca (LON:AZN) has today announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for Farxiga to reduce the risk of cardiovascular death or ...